Zhitong Finance App News, Baiyunshan (00874) issued an announcement. Recently, Guangzhou Baiyunshan Zhongyi Pharmaceutical Co., Ltd. (hereinafter referred to as “Zhongyi Pharmaceutical”), a subsidiary of Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. (hereinafter referred to as “the Company”), received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration to treat the new functions of eye disability tablets.

On May 9, 2026, Zhongyi Pharmaceutical submitted a clinical trial application to the State Drug Administration to improve the function of eye protection tablets, which was accepted on May 15, 2026. Eye relief tablets have the effect of nourishing the liver and kidney and reducing freckles.

Eye relief tablets have the effect of nourishing the liver and kidney and reducing freckles. It is used for dryness and discomfort, monocular diplopia, lower back and knee weakness, or mild vision loss due to liver and kidney deficiency; early and middle stage senile cataracts have the above symptoms. This product is a traditional Chinese medicine compound preparation that has already been marketed. This time, it is an application for additional clinical trial applications for dry eyes.

As of the date of this announcement, Zhongyi Pharmaceutical has invested approximately RMB 10.1114 million (RMB, same below) in exploratory clinical research on the efficacy, mechanism, and efficacy of eye patch for treating dry eye syndrome.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.